St. Jude Medical, Inc. (NYSE: STJ) reiterated to Perform with price target $64 by Oppenheimer
Oppenheimer reiterated St. Jude Medical, Inc. (NYSE: STJ) to Perform with
price target $64. Previously Oppenheimer rated Perform St. Jude Medical, Inc. (NYSE: STJ) on 07/14/2010, when the stock price was $37.06.
St. Jude Medical, Inc.
(St. Jude)develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. The Company operates in four business segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation Systems (Neuro). On July 3, 2008, the Company completed the acquisition of EP MedSystems, Inc. On December 19, 2008, St. Jude acquired Radi Medical Systems. On December 22, 2008, St. Jude acquired MediGuide Inc.
Funds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies.
Funds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority.
Funds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.